Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- August Listing OK’ed for Evrysdi, Veklury, Verquvo, 2 CGRP Migraine Meds and More
August 4, 2021
- Trintellix to Face 4.3% Price Cut under CEA Scheme, No Change for Coralan
August 4, 2021
- Delytact Gets 1.43 Million Yen Price Tag
August 4, 2021
- Temodar Label Revised to Erase Caveat for Combo Cancer Therapy
August 4, 2021
- New Pharma Industry Vision to Push Predictability for Investment Recovery: Draft Outline
August 3, 2021
- MHLW’s COVID-19 Guide Adds Chugai’s Cocktail Therapy
August 3, 2021
- Veklury to Join NHI Price List to Enter Normal Distribution Channel; Peak Sales Put at 18 Billion Yen
August 3, 2021
- Lilly’s Selpercatinib Clears Key Panel, in Line for September Approval
August 2, 2021
- Takeda’s Pevonedistat Set to Be 1st Legally Backed Sakigake Drug
August 2, 2021
- AstraZeneca Vaccine OK’ed for Age 40 and Up under Emergency Program
August 2, 2021
- GMP Inspections to Be Conducted Unannounced as Basic Rule: MHLW
July 30, 2021
- Forxiga Clears PAFSC, in Line to Become Japan’s 1st CKD Drug in August
July 29, 2021
- LDP Project Team on Drug Discovery Capabilities Likely to Meet Aug. 4
July 28, 2021
- Label Revisions Ordered for AstraZeneca’s COVID-19 Vaccine; Thrombocytopenia Added to Adverse Reactions
July 28, 2021
- Panels Agree to Add Risk of Thrombocytopenia to AstraZeneca Vaccine Label
July 27, 2021
- Prioritize Alfacalcidol Supply for Non-Osteoporosis Indications: MHLW
July 27, 2021
- Spread of Regional Formularies Will Depend on “Human Relationships and Consensus-Building”: Professor
July 26, 2021
- Chuikyo Reps Fret Negative Impact of Tougher Pledge Rule, but MHLW Says It’s Conducive to Stable Supplies
July 26, 2021
- Chuikyo Roughly Approves 11 Proposals to Hone CEA System
July 26, 2021
- MHLW to Tighten “Written Pledge” Rule on Generic Listings to Thwart Supply Issues
July 26, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…